SEC Form 4 · accession 0001209191-18-000343
AMICUS THERAPEUTICS, INC. · FOLD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John F Crowley
Officer — Chairman & CEO · Director
Period of report
Dec 28, 2017
Accepted (ET)
Jan 2, 2018 · 6:00 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001178879
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Dec 28, 2017 | M | 13,050 | $14.7507 | A | 341,051 | D | |
| Common StockF3 | Dec 28, 2017 | S | 13,050 | $14.7507 | D | 328,001 | D | |
| Common StockF4 | Dec 29, 2017 | M | 5,920 | $14.75 | A | 333,921 | D | |
| Common StockF5 | Dec 29, 2017 | S | 5,920 | $14.75 | D | 328,001 | D | |
| Common Stock | holding | — | — | — | 64,895 | I | By Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (right to buy) | $3.53 | Dec 28, 2017 | M | 13,050 | D | Jan 28, 2014 | Jan 28, 2023 | Common Stock | 13,050 | 7,458 | D |
| Stock Options (right to buy) | $3.53 | Dec 29, 2017 | M | 5,920 | D | Jan 28, 2014 | Jan 28, 2023 | Common Stock | 5,920 | 1,538 | D |
Explanation of responses
- F1The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017.
- F2This price is the weighted average purchase price for the transactions reported on this line. The prices for the transactions reported on this line range from $14.75 to $14.76. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
- F3This price is the weighted average sale price for the transactions reported on this line. The prices for the transactions reported on this line range from $14.75 to $14.76. The reporting person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F4This price of $14.75 is the sole purchase price for the transactions reported on this line.
- F5This price of $14.75 is the sole sale price for the transactions reported on this line.
Remarks
Shares were sold to fund the "Megan K. Crowley 2016 Special Needs Trust", a trust for the benefit of Mr. Crowley's child, with the balance of the proceeds used for general estate planning purposes. After these transactions, Mr. Crowley's percentage of shares beneficially owned is 1% of the company's outstanding shares.